ImmunityBio shares plunge after FDA warning over misleading ads By Investing.com

ImmunityBio received an FDA warning letter (dated March 13) for false and misleading promotion of its bladder cancer drug Anktiva; shares plunged as much as 30% at the open and were trading roughly 18% lower near 11:00am. The FDA cited misleading claims in a TV ad and podcast featuring CEO Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong that overstated efficacy (e.g., curing/preventing all cancers, single-injection claims) and omitted risk/approved-indication information. The company has 15 working days to respond with a remediation plan and corrective communications, creating near-term regulatory, reputational and commercialization risks that can keep the stock volatile.

Analysis

Regulatory enforcement around promotional claims has an outsized, immediate impact on small-cap oncology names because it directly increases the probability of commercial friction (payer pushback, hospital formulary delays) without changing underlying clinical efficacy. Expect near-term volatility driven by position-squaring: inexpensive options will see skew steepen, borrow rates for shorts jump, and retail-driven intraday flows amplify moves as institutions reassess thesis-conviction on weak governance.

Because senior management was central to the communications, the market will reprice governance risk alongside regulatory risk — that raises the likelihood of accelerated shareholder litigation, partner re-negotiations or carve-outs, and a longer sales ramp even if clinical outcomes remain unchanged. Competitors with established label clarity and larger commercial footprints (e.g., broad-portfolio immunotherapy incumbents) will see relative demand reallocation from payors and hospital systems over the next 3–12 months.

Time horizons split cleanly: days-to-weeks for sentiment and coverage actions (downgrades, research withdrawals), weeks-to-months for remediation communications and potential civil enforcement, and 6–24 months for any structural commercial consequences or M&A fallout. Reversal catalysts are narrow but powerful — transparent third-party remediation, independent audit, management change, or a positive clinical readout that materially expands label probability can compress risk premia quickly.

The best non-obvious second-order play is to trade the governance contagion rather than clinical binary risk: short-term hedges that profit from sentiment and liquidity dislocations will outperform outright fundamental calls until the issuer demonstrates disciplined remediation. Also monitor physician prescribing data and payer coverage memos — early indications there are the fastest signal of durable revenue impact.

Key Decisions for Investors

• Short IBRX equity (size 0.5–1.5% NAV) in the next 1–3 weeks to capture de-risking and sentiment flows; set tactical target of 30–60% downside and hard stop at 25% adverse move given high intraday volatility.
• Buy 3–6 month IBRX put protection (ATM or a put spread to finance premium) to hedge existing exposure — expect skew expansion and bid for puts; max loss = premium, directional payoff if regulatory noise escalates within 3 months.
• Pair trade: short IBRX / long MRK (0.5% / 0.5% NAV) as a relative-value hedge against sector contagion — MRK benefits from clearer labels and will outperform on payer repricing over 3–12 months.
• Small asymmetric long: buy 12–18 month IBRX LEAP calls (size 0.1–0.3% NAV) only after public independent remediation plan or management change is announced — low-cost optionality to capture rapid de-risking and potential multiple re-rating.